Circulating non-coding RNAs in recurrent and metastatic ovarian cancer

Abstract

Ovarian cancer has a poor outcome because it is usually detected at advanced tumor stages, and the majority of the patients develop disease relapse as a result of chemotherapy resistance. This most lethal gynecological malignancy metastasizes within the peritoneal fluid or ascites to pelvic and distal organs. In ovarian cancer progression and metastasis, small non-coding RNAs (ncRNAs), including long noncoding RNAs and microRNAs have been recognized as important regulators. Their dysregulation modulates gene expression and cellular signal pathways and can be detected in liquid biopsies. In this review, we provide an overview on circulating plasma and serum ncRNAs participating in tumor cell migration and invasion, and contributing to recurrence and metastasis of ovarian cancer. We will also discuss the development of potential, novel therapies using ncRNAs as target molecules or tumor markers for ovarian cancer.

Keywords

Ovarian cancer recurrence / metastasis / epithelial-mesemchmal transition / non-coding RNAs / chemotherapy / tumor markers

References

[1] Tucker BJ.Riboswitches as versatile gene control elements..Curr Opin Struct Biol2005;15:342-8

[2] Narberhaus F,Chowdhury S.RNA thermometers..FEMS Microbiol Rev2006;30:3-16

[3] Diener TO.Potato spindle tuber “virus”. IV. A replicating, low molecular weight RNA..Virology1971;45:411-28

[4] Sanger HL,Riesner D,Kleinschmidt AK.Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures..Proc Natl Acad Sci U S A1976;73:3852-6 PMCID:PMC431239

[5] Zhan ZH,Li LP,Yi HC.Accurate prediction of ncRNA-protein interactions from the integration of sequence and evolutionary information..Front Genet2018;9:458 PMCID:PMC6186793

[6] Chan JJ.Noncoding RNA: RNA regulatory networks in cancer..Int J Mol Sci2018;19: PMCID:PMC5983611

[7] Fang XY,Leng RX.Long noncoding RNAs: novel insights into gastric cancer..Cancer Lett2015;356:357-66

[8] Weng W,Goel A.Piwi-interacting RNAs (piRNAs) and cancer: Emerging biological concepts and potential clinical implications..Biochim Biophys Acta Rev Cancer2019;1871:160-9 PMCID:PMC6392428

[9] Schwarzenbach H,Pantel K.Cell-free nucleic acids as biomarkers in cancer patients..Nat Rev Cancer2011;11:426-37

[10] Simpson RJ,Moritz RL.Exosomes: proteomic insights and diagnostic potential..Expert Rev Proteomics2009;6:267-83

[11] Schwarzenbach H.MicroRNA shuttle from cell-to-cell by exosomes and its impact in cancer..Noncoding RNA2019;5: PMCID:PMC6468647

[12] Heneghan HM,Lowery AJ,Kerin MJ.MicroRNAs as Novel Biomarkers for Breast Cancer..J Oncol2009;2009:950201 PMCID:PMC2712985

[13] Jayson GC,Kitchener HC.Ovarian cancer..Lancet2014;

[14] McGuire S.World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015..Adv Nutr2016;7:418-9 PMCID:PMC4785485

[15] Lheureux S,Oza AM.Epithelial ovarian cancer: Evolution of management in the era of precision medicine..CA Cancer J Clin2019;

[16] Mutch DG.2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer..Gynecol Oncol2014;133:401-4

[17] Meinhold-Heerlein I.The heterogeneity of ovarian cancer..Arch Gynecol Obstet2014;289:237-9

[18] Wong TS,Chan JY.Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors..Biomed Res Int2014;2014:921564 PMCID:PMC4147210

[19] Tang HF,Hemmings BA,Hu ZQ.AKT-ions with a TWIST between EMT and MET..Oncotarget2016;7:62767-77 PMCID:PMC5308764

[20] Satelli A.Vimentin in cancer and its potential as a molecular target for cancer therapy..Cell Mol Life Sci2011;68:3033-46 PMCID:PMC3162105

[21] Ashaie MA.Cadherins: the superfamily critically involved in breast cancer..Curr Pharm Des2016;22:616-38

[22] Lamouille S,Derynck R.Molecular mechanisms of epithelial-mesenchymal transition..Nat Rev Mol Cell Biol2014;15:178-96 PMCID:PMC4240281

[23] Roane BM,Birrer MJ.Review: targeting the transforming growth factor-beta pathway in ovarian cancer..Cancers (Basel)2019;11: PMCID:PMC6562901

[24] Arend RC,Straughn JM Jr.The Wnt/beta-catenin pathway in ovarian cancer: a review..Gynecol Oncol2013;131:772-9

[25] Brzozowa-Zasada M,Michalski M,Kurek J.Notch and its oncogenic activity in human malignancies..Eur Surg2017;49:199-209 PMCID:PMC5653712

[26] Ediriweera MK,Samarakoon SR.Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance..Semin Cancer Biol2019;

[27] Bilyk O,Jewer M.Epithelial-to-mesenchymal transition in the female reproductive tract: from normal functioning to disease pathology..Front Oncol2017;7:145 PMCID:PMC5497565

[28] Klymenko Y,Stack MS.Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer..Cancers (Basel)2017;9: PMCID:PMC5575607

[29] Barbolina MV.Molecular mechanisms regulating organ-specific metastases in epithelial ovarian carcinoma..Cancers (Basel)2018;10: PMCID:PMC6266311

[30] Stewart DJ.Mechanisms of resistance to cisplatin and carboplatin..Crit Rev Oncol Hematol2007;63:12-31

[31] Yang CH.Taxol((R)): the first microtubule stabilizing agent..Int J Mol Sci2017;18: PMCID:PMC5578123

[32] Motohara T.Ovarian Cancer Stemness: Biological and Clinical Implications for Metastasis and Chemotherapy Resistance..Cancers (Basel)2019;11: PMCID:PMC6678827

[33] Ottevanger PB.Ovarian cancer stem cells more questions than answers..Semin Cancer Biol2017;44:67-71

[34] Liao JQ,Tchabo N,Beck A.Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism..PLoS One2014;9: PMCID:PMC3883678

[35] Bast RC Jr,St John E,Niloff JM.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer..N Engl J Med1983;309:883-7

[36] Bondza PK,Akoum A.Insights into endometriosis-associated endometrial dysfunctions: a review..Front Biosci (Elite Ed)2009;1:415-28

[37] Biggs WS.Diagnosis and Management of Adnexal Masses..Am Fam Physician2016;93:676-81

[38] Yang WL,Bast RC Jr.The role of biomarkers in the management of epithelial ovarian cancer..Expert Rev Mol Diagn2017;17:577-91 PMCID:PMC5823503

[39] Abu Hassaan SO.Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125..Dan Med J2018;65:

[40] Brenk A,Balis M,Janosz I.Usefulness of HE4 protein in differentiation of pelvic masses in woman..Prz Menopauzalny2019;18:27-32 PMCID:PMC6528042

[41] Dewan R,Jindal M.Diagnostic performance of serum human epididymis protein 4 (HE4) for prediction of malignancy in ovarian masses..Asian Pac J Cancer Prev2019;20:1103-8

[42] Bartel DP.MicroRNAs: target recognition and regulatory functions..Cell2009;136:215-33 PMCID:PMC3794896

[43] Fabian MR.The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC..Nat Struct Mol Biol2012;19:586-93

[44] Griffiths-Jones S.miRBase: the microRNA sequence database..Methods Mol Biol2006;342:129-38

[45] Griffiths-Jones S,van Dongen S,Enright AJ.miRBase: microRNA sequences, targets and gene nomenclature..Nucleic Acids Res2006;34:D140-4 PMCID:PMC1347474

[46] Perkel JM.Visiting “noncodarnia”..Biotechniques2013;54:3013-4

[47] Ren H,Chen L,Liu L.Genome-wide analysis of long non-coding RNAs at early stage of skin pigmentation in goats (Capra hircus)..BMC Genomics2016;17:67 PMCID:PMC4719336

[48] Matsumoto A,Pandolfi PP.SPAR, a lncRNA encoded mTORC1 inhibitor..Cell Cycle2017;16:815-6 PMCID:PMC5444354

[49] Anderson DM,Chang CL,Nelson BR.A micropeptide encoded by a putative long noncoding RNA regulates muscle performance..Cell2015;160:595-606 PMCID:PMC4356254

[50] Pauli A,Valen E,Gagnon JA.Toddler: an embryonic signal that promotes cell movement via Apelin receptors..Science2014;343:1248636 PMCID:PMC4107353

[51] Smith JE,Kline N,Geisler S.Translation of small open reading frames within unannotated RNA transcripts in Saccharomyces cerevisiae..Cell Rep2014;7:1858-66 PMCID:PMC4105149

[52] Ji Z,Regev A.Many lncRNAs, 5’UTRs, and pseudogenes are translated and some are likely to express functional proteins..Elife2015;4:e08890 PMCID:PMC4739776

[53] Ma XY,Wang JL,Wang XC.Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells..BMC Genomics2015;16:676 PMCID:PMC4559210

[54] Kwok ZH.Long noncoding RNAs: lincs between human health and disease..Biochem Soc Trans2017;45:805-12

[55] Kopp F.Functional classification and experimental dissection of long noncoding RNAs..Cell2018;172:393-407 PMCID:PMC5978744

[56] Zhan L,Wei B.Long non-coding RNAs in ovarian cancer..J Exp Clin Cancer Res2018;37:120 PMCID:PMC6008930

[57] Sai Lakshmi S.piRNABank: a web resource on classified and clustered Piwi-interacting RNAs..Nucleic Acids Res2008;36:D173-7 PMCID:PMC2238943

[58] Kozomara A.miRBase: annotating high confidence microRNAs using deep sequencing data..Nucleic Acids Res2014;42:D68-73 PMCID:PMC3965103

[59] Hammond SM.An overview of microRNAs..Adv Drug Deliv Rev2015;87:3-14 PMCID:PMC4504744

[60] Griffiths-Jones S,Marshall M,Eddy SR.Rfam: annotating non-coding RNAs in complete genomes..Nucleic Acids Res2005;33:D121-4 PMCID:PMC540035

[61] Girard A,Hannon GJ.A germline-specific class of small RNAs binds mammalian Piwi proteins..Nature2006;442:199-202

[62] Chen C,Xu G.Overexpression of PIWI proteins in human stage III epithelial ovarian cancer with lymph node metastasis..Cancer Biomark2013;13:315-21

[63] Aravin A,Pfeffer S,Landgraf P.A novel class of small RNAs bind to MILI protein in mouse testes..Nature2006;442:203-7

[64] Yin H.An epigenetic activation role of Piwi and a Piwi-associated piRNA in Drosophila melanogaster..Nature2007;450:304-8

[65] Huang XA,Sweeney S,Snyder M.A major epigenetic programming mechanism guided by piRNAs..Dev Cell2013;24:502-16 PMCID:PMC3600162

[66] Andersen PR,Vunjak M.A heterochromatin-dependent transcription machinery drives piRNA expression..Nature2017;549:54-9 PMCID:PMC5590728

[67] Aravin AA,Brennecke J.The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race..Science2007;318:761-4

[68] Wilson RC.Molecular mechanisms of RNA interference..Annu Rev Biophys2013;42:217-39 PMCID:PMC5895182

[69] Fu A,Zhu Y.Epigenome-wide analysis of piRNAs in gene-specific DNA methylation..RNA Biol2014;11:1301-12 PMCID:PMC4615395

[70] Yan H,Sun CY,Deng J.piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma..Leukemia2015;29:196-206

[71] Watanabe T,Tsukiyama T,Okuno T.Identification and characterization of two novel classes of small RNAs in the mouse germline: retrotransposon-derived siRNAs in oocytes and germline small RNAs in testes..Genes Dev2006;20:1732-43 PMCID:PMC1522070

[72] Li D,Gao Y,Wang Y.piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4..Int J Mol Med2016;38:927-36

[73] Yao J,Fang BB,Cheng BL.piR-651 and its function in 95-D lung cancer cells..Biomed Rep2016;4:546-50 PMCID:PMC4840783

[74] Law PT,Ching AK,Co NN.Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma..J Hepatol2013;58:1165-73

[75] Wang QE,Milum K.Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment..Mutat Res2011;708:59-68 PMCID:PMC3091508

[76] Salmena L,Tay Y,Pandolfi PP.A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?.Cell2011;146:353-8 PMCID:PMC3235919

[77] Tay Y,Salmena L,Tan SM.Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs..Cell2011;147:344-57 PMCID:PMC3235920

[78] Cesana M,Legnini I,Sthandier O.A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA..Cell2011;147:358-69 PMCID:PMC3234495

[79] Muller V,Steinbach B,Schwarzenbach H.Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer..Mol Oncol2019;13:1137-49 PMCID:PMC6487715

[80] Zhang G,Zhang Y,Fan W.Characterization of dysregulated lncRNA-mRNA network based on ceRNA hypothesis to reveal the occurrence and recurrence of myocardial infarction..Cell Death Discov2018;4:35 PMCID:PMC5841419

[81] Xia T,Jiang X,Xiao B.Long noncoding RNA associated-competing endogenous RNAs in gastric cancer..Sci Rep2014;4:6088 PMCID:PMC4133709

[82] Poliseno L,Zhang J,Haveman WJ.A coding-independent function of gene and pseudogene mRNAs regulates tumour biology..Nature2010;465:1033-8 PMCID:PMC3206313

[83] An Y,Ji S.Pseudogenes regulate parental gene expression via ceRNA network..J Cell Mol Med2017;21:185-92 PMCID:PMC5192809

[84] Pasquinelli AE.MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship..Nat Rev Genet2012;13:271-82

[85] Lenkala D,Gamazon ER,Im HK.The impact of microRNA expression on cellular proliferation..Hum Genet2014;133:931-8 PMCID:PMC4677487

[86] Calin GA.MicroRNA signatures in human cancers..Nat Rev Cancer2006;6:857-66

[87] Qi X,Wu N,Wang X.ceRNA in cancer: possible functions and clinical implications..J Med Genet2015;52:710-8

[88] de Giorgio A,Harding V,Castellano L.Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN..Mol Cell Biol2013;33:3976-82 PMCID:PMC3811677

[89] Esquela-Kerscher A.Oncomirs - microRNAs with a role in cancer..Nat Rev Cancer2006;6:259-69

[90] Karreth FA.ceRNA cross-talk in cancer: when ce-bling rivalries go awry..Cancer Discov2013;3:1113-21 PMCID:PMC3801300

[91] Tay Y,Pandolfi PP.The multilayered complexity of ceRNA crosstalk and competition..Nature2014;505:344-52 PMCID:PMC4113481

[92] Do D.Cancerin: a computational pipeline to infer cancer-associated ceRNA interaction networks..PLoS Comput Biol2018;14:e1006318 PMCID:PMC6072113

[93] Arnberg AC,Grivell LA,Borst P.Some yeast mitochondrial RNAs are circular..Cell1980;19:313-9

[94] Hsu MT.Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells..Nature1979;280:339-40

[95] Xu Y.An overview of the main circRNA databases..Non-coding RNA Investig2017;1:22-6

[96] Wang Y,Gong Z,Yang M.Circular RNAs in human cancer..Mol Cancer2017;16:25 PMCID:PMC5282898

[97] Wang Y.Efficient backsplicing produces translatable circular mRNAs..RNA2015;21:172-9 PMCID:PMC4338345

[98] Tatomer DC.An unchartered journey for ribosomes: circumnavigating circular RNAs to produce proteins..Mol Cell2017;66:1-2

[99] Schneider T.Circular RNAs: coding or noncoding?.Cell Res2017;27:724-5

[100] Liu KS,Mao XD,Chen YJ.Biological functions of circular RNAs and their roles in occurrence of reproduction and gynecological diseases..Am J Transl Res2019;11:1-15 PMCID:PMC6357300

[101] Li Z,Bao C,Lin M.Exon-intron circular RNAs regulate transcription in the nucleus..Nat Struct Mol Biol2015;22:256-64

[102] Conn VM,Nayak A,Capovilla G.A circRNA from SEPALLATA3 regulates splicing of its cognate mRNA through R-loop formation..Nat Plants2017;3:17053

[103] Cortes-Lopez M.Emerging functions of circular RNAs..Yale J Biol Med2016;89:527-37 PMCID:PMC5168830

[104] Ahmed I,Andrews SS,Mohamoud YA.Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma..Oncotarget2016;7:36366-81 PMCID:PMC5095006

[105] Xu Z,Zeng S,Chen X.Circular RNAs: clinical relevance in cancer..Oncotarget2018;9:1444-60 PMCID:PMC5787450

[106] Fire A,Montgomery MK,Driver SE.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans..Nature1998;391:806-11

[107] Hamilton AJ.A species of small antisense RNA in posttranscriptional gene silencing in plants..Science1999;286:950-2

[108] Dana H,Mahmoodzadeh H,Rezaiean O.Molecular mechanisms and biological functions of siRNA..Int J Biomed Sci2017;13:48-57 PMCID:PMC5542916

[109] Urban-Klein B,Abuharbeid S,Aigner A.RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo..Gene Ther2005;12:461-6

[110] Landen CN,Sood AK.EphA2 as a target for ovarian cancer therapy..Expert Opin Ther Targets2005;9:1179-87

[111] Singh A,Jain NK.Advances in siRNA delivery in cancer therapy..Artif Cells Nanomed Biotechnol2018;46:274-83

[112] Gary DJ,Won YY.Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery..J Control Release2007;121:64-73

[113] Jere D,Arote R,Choi YJ.Degradable polyethylenimines as DNA and small interfering RNA carriers..Expert Opin Drug Deliv2009;6:827-34

[114] Lungwitz U,Blunk T.Polyethylenimine-based non-viral gene delivery systems..Eur J Pharm Biopharm2005;60:247-66

[115] Choi SW,Mok H.Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide..Biotechnol Prog2010;26:57-63

[116] Oliveira S,Kranenburg O,Schiffelers RM.Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes..Int J Pharm2007;331:211-4

[117] Hou KK,Ratner L,Wickline SA.Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides..ACS Nano2013;7:8605-15 PMCID:PMC4013830

[118] Zuhorn IS,Hoekstra D.Gene delivery by cationic lipid vectors: overcoming cellular barriers..Eur Biophys J2007;36:349-62

[119] Kim SI,Choi TH,Cheon GJ.Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I..Mol Ther2007;15:1145-52

[120] Akinc A,Goldberg M,Busini V.A combinatorial library of lipid-like materials for delivery of RNAi therapeutics..Nat Biotechnol2008;26:561-9 PMCID:PMC3014085

[121] Lee SK,Beloor J,Kumar P.Cell-specific siRNA delivery by peptides and antibodies..Methods Enzymol2012;502:91-122

[122] Cesarone G,Chen CP.Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1..Bioconjug Chem2007;18:1831-40

[123] Lorenz C,John M,Unverzagt C.Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells..Bioorg Med Chem Lett2004;14:4975-7

[124] Blum JS.High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine..J Control Release2008;129:66-72 PMCID:PMC2494593

[125] Kataoka K,Nagasaki Y.Block copolymer micelles for drug delivery: design, characterization and biological significance..Adv Drug Deliv Rev2001;47:113-31

[126] Landen CN,Mangala LS,Bucana C.Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer..Cancer Biol Ther2006;5:1708-13

[127] Goldberg MS.siRNA delivery for the treatment of ovarian cancer..Methods2013;63:95-100

[128] Deng J,Jiang Z,Li H.Enhancement of ovarian cancer chemotherapy by delivery of multidrug-resistance gene small interfering RNA using tumor targeting Salmonella..J Obstet Gynaecol Res2015;41:615-22

[129] Huang YH,Peng W,Love K.Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis..Proc Natl Acad Sci U S A2009;106:3426-30 PMCID:PMC2651300

[130] Ren Y,von Maltzhan G,Cowley GS.Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4..Sci Transl Med2012;4:147ra12 PMCID:PMC3633234

[131] Ma J,Yung S,Cao Y.Blocking stemness and metastatic properties of ovarian cancer cells by targeting p70(S6K) with dendrimer nanovector-based siRNA delivery..Mol Ther2018;26:70-83 PMCID:PMC5763163

[132] van den Brand D,Massuger L.siRNA in ovarian cancer - Delivery strategies and targets for therapy..J Control Release2018;283:45-58

[133] Halbur C,Chen M,Chung EJ.siRNA-conjugated nanoparticles to treat ovarian cancer..SLAS Technol2019;24:137-50

[134] Meng X,Muller V,Milde-Langosch K.Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients..Br J Cancer2015;113:1358-66 PMCID:PMC4815782

[135] Zhou J,Tan H,Zhu X.Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma..Oncol Rep2015;33:2915-23

[136] Guo F,Lin Y,Wang L.Serum microRNA-92 expression in patients with ovarian epithelial carcinoma..J Int Med Res2013;41:1456-61

[137] Yoshimura A,Nakamura K,Nakatsuka E.Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells..BMC Cancer2018;18:1065 PMCID:PMC6217763

[138] Xu Y,Zheng J,Zhao S.MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor..FEBS Open Bio2017;7:1258-66 PMCID:PMC5586337

[139] Zuberi M,Mir R,Ray PC.Utility of Serum miR-125b as a diagnostic and prognostic indicator and its alliance with a panel of tumor suppressor genes in epithelial ovarian cancer..PLoS One2016;11:e0153902 PMCID:PMC4836713

[140] Chao A,Chen HC,Tsai CL.Serum microRNAs in clear cell carcinoma of the ovary..Taiwan J Obstet Gynecol2014;53:536-41

[141] Wu H,Wang K,Hao Q.MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1..Biochem Biophys Res Commun2013;441:693-700

[142] Zuberi M,Khan I,Guru SA.The promising signatures of circulating microRNA-145 in epithelial ovarian cancer patients..Microrna2019;

[143] Gong L,Gao Y.Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis..Biomed Pharmacother2016;83:58-63

[144] Chen H,Zhang L,Wang H.MicroRNA-183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian caner..Am J Transl Res2016;8:1748-55 PMCID:PMC4859903

[145] Ren X,Cong H,Ni H.Diagnostic model of serum miR-193a-5p, HE4 and CA125 improves the diagnostic efficacy of epithelium ovarian cancer..Pathol Oncol Res2018;24:739-44

[146] Benson EA,Liu Y,Matei D.Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating miRNAs concentrations: a pilot study..PLoS One2015;10:e0141279 PMCID:PMC4612782

[147] Zuberi M,Gandhi G,Saxena A.The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer..Tumour Biol2016;37:11259-66

[148] Márton E,Penyige A,Hegedus L.Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer..J Biotechnol2019;297:58-65

[149] Meng X,Milde-Langosch K,Pantel K.Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer..Oncotarget2016;7:16923-35 PMCID:PMC4941360

[150] Zuberi M,Das J,Javid J.Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features..Clin Transl Oncol2015;17:779-87

[151] Su YY,Guo ZR,Bai TT.Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer..J Ovarian Res2019;12:6 PMCID:PMC6341583

[152] Yang L,Zhang XW,Yan XT.MiR-376a promotion of proliferation and metastases in ovarian cancer: Potential role as a biomarker..Life Sci2017;173:62-7

[153] Tang X,Huang Y,Lin F.miR-423-5p serves as a diagnostic indicator and inhibits the proliferation and invasion of ovarian cancer..Exp Ther Med2018;15:4723-30 PMCID:PMC5960745

[154] Salem M,Bernaudo S,Ye G.miR-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway..Cancer Res2018;78:4175-90

[155] Chen X,Wang X,Zhu Q.Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization..Oncol Rep2017;38:522-8

[156] Günel T,Dogan B,Hosseini MK.Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer..Arch Gynecol Obstet2018;298:1173-80

[157] Qiu JJ,Tang XY,Lin YY.Exosomal metastasisassociated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer..Int J Biol Sci2018;14:1960-73 PMCID:PMC6299373

[158] Ma J.LINK-A lncRNA promotes migration and invasion of ovarian carcinoma cells by activating TGF-beta pathway..Biosci Rep2018;38: PMCID:PMC6137249

[159] Zhang H,Tang S.LINK-A long non-coding RNA (lncRNA) participates in metastasis of ovarian carcinoma and upregulates hypoxia-inducible factor 1 (HIF1alpha)..Med Sci Monit2019;25:2221-7 PMCID:PMC6446655

[160] Lheureux S,Vergote I.Epithelial ovarian cancer..Lancet2019;393:1240-53

[161] Wang X,Zhou L,Zhang LM.Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network..Oncol Rep2018;40:2659-73 PMCID:PMC6151886

[162] Wang Y,Tang W,Xu L.miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-kappaB in high-grade serous ovarian carcinoma..Cell Death Differ2017;24:2089-100 PMCID:PMC5686346

[163] Li N,Wang H,Jia X.MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells..PLoS One2015;10:e0128886 PMCID:PMC4456206

[164] Zhang Y.Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer..Braz J Med Biol Res2017;50:e6104 PMCID:PMC5479390

[165] Kwong J,Wong KK,Archibald KM.Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells..Neoplasia2009;11:529-41 PMCID:PMC2685442

[166] Zeller C,Steele NL,Walley AJ.Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling..Oncogene2012;31:4567-76

[167] Carnero A,Renner O,Leal JF.The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications..Curr Cancer Drug Targets2008;8:187-98

[168] Gasparri ML,Farooqi AA,Taghavi K.MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance..J Cancer Res Clin Oncol2018;144:2313-8

[169] Xu Q,Qian X,Jiang Y.MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis..Nucleic Acids Res2012;40:761-74 PMCID:PMC3258133

[170] Du W,Sun Q.LncRNA LINC00319 accelerates ovarian cancer progression through miR-423-5p/NACC1 pathway..Biochem Biophys Res Commun2018;507:198-202

[171] Meng L,Ji R,Yan X.Targeting the BDNF/TrkB pathway for the treatment of tumors..Oncol Lett2019;17:2031-9 PMCID:PMC6341806

[172] Zheng HB,Liu BP.miRNA-101 inhibits ovarian cancer cells proliferation and invasion by down-regulating expression of SOCS-2..Int J Clin Exp Med2015;8:20263-70 PMCID:PMC4723784

[173] Guo F,Hu L,Sood AK.MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma..Oncol Rep2014;31:2021-8 PMCID:PMC4020617

[174] Zavesky L,Weinberger V,Hanzikova V.Ascites-derived extracellular microRNAs as potential biomarkers for ovarian cancer..Reprod Sci2019;26:510-22 PMCID:PMC6421628

[175] Press JZ,Pitteri SJ,Garcia R.Microparticles from ovarian carcinomas are shed into ascites and promote cell migration..Int J Gynecol Cancer2012;22:546-52

[176] Braga EA,Kushlinskii NE.Molecular mechanisms of ovarian carcinoma metastasis: key genes and regulatory MicroRNAs..Biochemistry (Mosc)2017;82:529-41

[177] Zhou J,Zhou B.miR-183 modulated cell proliferation and apoptosis in ovarian cancer through the TGF-beta/Smad4 signaling pathway..Int J Mol Med2019;43:1734-46 PMCID:PMC6414177

[178] Yan H,Li P,Lin J.Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis..J Exp Clin Cancer Res2018;37:237 PMCID:PMC6154914

[179] Zou J,Wang Q,Yang Z.Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1..Am J Transl Res2017;9:1357-68 PMCID:PMC5376026

[180] Meng X,Milde-Langosch K,Pantel K.Circulating cell-free miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer..Adv Exp Med Biol2016;924:3-8

[181] Koutsaki M,Spandidos DA.The miR-200 family in ovarian cancer..Oncotarget2017;8:66629-40 PMCID:PMC5630443

[182] Hurteau GJ,Spivack SD.Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin..Cancer Res2007;67:7972-6

[183] Kong F,Wang Z,Weng D.miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1..J Huazhong Univ Sci Technolog Med Sci2011;31:543

[184] Dong R,Zhang Q,Li Y.miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma..Oncotarget2014;5:10816-29 PMCID:PMC4279412

[185] Zhu X,Xie C,Liu Y.miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6..Int J Cancer2014;135:1286-96

[186] Hu J,Chen J,Zhao W.The circular RNA circ-ITCH suppresses ovarian carcinoma progression through targeting miR-145/RASA1 signaling..Biochem Biophys Res Commun2018;505:222-8

[187] Song K,Chen Y,Yao Q.Emodin inhibits TGF-beta2 by activating the FOXD3/miR199a axis in ovarian cancer cells in vitro..Oncol Rep2018;39:2063-70 PMCID:PMC5928761

[188] Bryzgunova OE.Extracellular nucleic acids in urine: sources, structure, diagnostic potential..Acta Naturae2015;7:48-54 PMCID:PMC4610164

[189] Sun Y.New insights into long non-coding RNA MALAT1 in cancer and metastasis..Cancers (Basel)2019;11: PMCID:PMC6406606

[190] Smith B,Bhowmick NA.MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine..Endocr Relat Cancer2017;24:R157-R72 PMCID:PMC5446589

[191] Zhang L,Tang L.MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer..J Exp Clin Cancer Res2019;38:53 PMCID:PMC6360685

[192] Adams BD,Slack FJ.The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas..Expert Opin Ther Targets2016;20:737-53 PMCID:PMC4922263

[193] Beg MS,Sachdev J,Kang YK.Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors..Invest New Drugs2017;35:180-8 PMCID:PMC5893501

[194] Lawrie CH,Dunlop HM,Liggins AP.Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma..Br J Haematol2008;141:672-5

[195] Mitchell PS,Kroh EM,Wyman SK.Circulating microRNAs as stable blood-based markers for cancer detection..Proc Natl Acad Sci U S A2008;105:10513-8 PMCID:PMC2492472

[196] Schwarzenbach H,Calin G.Data Normalization Strategies for MicroRNA Quantification..Clin Chem2015; PMCID:PMC4890630

[197] Bronkhorst AJ,Pretorius PJ.Cell-free DNA: preanalytical variables..Clin Chim Acta2015;450:243-53

[198] Tiberio P,Angeloni V,Appierto V.Challenges in using circulating miRNAs as cancer biomarkers..Biomed Res Int2015;2015:731479 PMCID:PMC4385632